CANbridge Pharmaceuticals and UMass Chan Medical School Presented Poster from the Preclinical Results of CAN203 at ASGCT 2023 Annual Meeting
Shots:
- The study showed improved life span and motor function in a mouse model of SMA than the benchmark vector-treated mice when delivered via ICV injection at high (3.3x10^13 vg/kg) and low (1.1x10^13 vg/kg) doses
- At the high dose both cohorts had 100% survival along with significantly better (p=0.043) rotarod performance at the end of the 90-day, while at the low dose, had better survival. No DRG toxicity associated with superior SMN expression was observed.
- Also, a very high ICV dose (1.1x10^14 vg/kg) of CAN203 in healthy mice maintained superior SMN protein expression after 1yr. vs the same dose of the benchmark therapy
Ref: Businesswire | Image: CANbridge
Related News:- CANbridge Reports P-I/II Study Results of CAN008 for Glioblastoma Multiforme
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
